#	Pagina
attuale pagina	/open-h2020/projects/205372/index.html

Opendata, web and dolomites

ADC

Next-Generation Antibody-Drug Conjugates for safer and more effective cancer therapies

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

ADC project word cloud

Explore the words cloud of the ADC project. It provides you a very rough idea of what is the project "ADC" about.

drug advantage tumour picomolar therapy discrimination cures destroying immune antibodies subnanomolar sites healthy technologies cell responsible slow stem breast competitors showed relapse metastasis approved seattle alternative lines resistance screen screening toxic cscs tested validated potency avoiding hallmark cancers types exclusively sensitive designed antigen activates carries resistant adcs variety conjugated first adverse compound kill payload 9m killing molecular oncolinx chemotherapies durable azonafide complexes antibody integral effectiveness perform shown remaining immunogen invasive genetics systemic express action innovative linker 2 nci human drugs chemotherapy thereby treatment 1x10 mechanism platform conjugates 98 cancer linked cells malignant valid

Project "ADC" data sheet

The following table provides information about the project.

Coordinator	ONCOLINX UK LIMITED Organization address address: 72 GREAT SUFFOLK STREET city: LONDON postcode: SE1 0BL website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Project website	http://www.oncolinx.com/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2016-2017
Funding Scheme	SME-1
Starting year	2016
Duration (year-month-day)	from 2016-05-01 to 2016-09-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ONCOLINX UK LIMITED ONCOLINX UK LIMITED Organization address address: 72 GREAT SUFFOLK STREET city: LONDON postcode: SE1 0BL website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	coordinator	50˙000.00

Map

Project objective

Oncolinx has developed a novel molecular platform allowing for non-invasive and highly effective cancer cures. The platform carries a killing drug (Azonafide), linked to an antibody, specifically targeting and destroying only malignant tumour cells. These molecular complexes are called Antibody Drug Conjugates (ADCs) and represent a strong, valid alternative to current chemotherapies. Oncolinx’s innovative linker/payload technology enables the Azonafide platform to perform a sensitive discrimination between healthy and cancer cells, thereby avoiding adverse side-effects of chemotherapy. ADCs enhance the effectiveness of a systemic treatment and have the advantage of targeting only tumour sites within the same therapy. Oncolinx’s drugs are effective against drug resistant cancers, as well as cancer stem cells (CSCs)—cells directly responsible for drug-resistance, metastasis, and relapse. In addition, Oncolinx’s technology activates the immune system against the tumour, which is an integral hallmark of durable responses. Although Oncolinx’s platform is designed to be adopted for drug-resistant breast cancers as first application, the Azonafide payload potency has been validated across all NCI-60 cell lines screening for different tumour types. The NCI-60 Human Tumour Cell Lines Screen also showed that the Azonafide payload, when conjugated with Oncolinx linker technology to specific antibodies, can kill up to 98.2% of cancer cells while remaining non-toxic to cells that do not express the antigen. NCI-60 screening has shown subnanomolar-picomolar potency across cancers (1x10-9M). While a variety of ADCs compound are currently developed and tested, only two ADCs have been approved so far. However, because Azonafide platform has a unique mechanism of action, Oncolinx can exclusively target slow growing cancers, drug resistant cancers, and other cancers that cannot be treated by the technologies of the two competitors (Seattle Genetics and ImmunoGen).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ADC" are provided by the European Opendata Portal: CORDIS opendata.